A potent nontoxic antitumor drug, 2-hydroxyoleic acid (, 2OHOA) used for membrane lipid therapy, was selected as a self-assembly inducer due to its ability to form nanoparticles (NPs) in water. For this purpose, it was conjugated with a series of anticancer drugs through a disulfide-containing linker to enhance cell penetration and to secure drug release inside the cell. The antiproliferative evaluation of the synthesized NP formulations against three human tumor cell lines (biphasic mesothelioma MSTO-211H, colorectal adenocarcinoma HT-29, and glioblastoma LN-229) showed that nanoassemblies - exhibit antiproliferative activity at micromolar and submicromolar concentrations. Furthermore, the ability of the disulfide-containing linker to promote cellular effects was confirmed for most nanoformulations. Finally, induced intracellular ROS increase in glioblastoma LN-229 cells similarly to free drug , and such elevated production was decreased by pretreatment with the antioxidant -acetylcysteine. Also, nanoformulations and confirmed the mechanism of action of the free drugs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220756PMC
http://dx.doi.org/10.3390/ph16050722DOI Listing

Publication Analysis

Top Keywords

2-hydroxyoleic acid
8
self-assembly inducer
8
disulfide-containing linker
8
glioblastoma ln-229
8
acid self-assembly
4
inducer anti-cancer
4
anti-cancer drug-centered
4
drug-centered nanoparticles
4
nanoparticles potent
4
potent nontoxic
4

Similar Publications

Targeting the Notch-Furin axis with 2-hydroxyoleic acid: a key mechanism in glioblastoma therapy.

Cell Oncol (Dordr)

October 2024

R&D Department, Laminar Pharmaceuticals, C/Isaac Newton, Palma de Mallorca, 07121, Spain.

Article Synopsis
  • Glioblastomas (GBMs) are aggressive brain tumors that resist treatment; the study investigates the effects of 2OHOA, a drug currently in clinical trials, on the Notch signaling pathway associated with tumor growth.
  • 2OHOA was found to inhibit Notch2 and Notch3 through different mechanisms: it affects Notch2 processing by inactivating furin and downregulates Notch3 transcriptionally.
  • The research emphasizes that targeting Notch signaling may enhance 2OHOA's anticancer effects, presenting a potential new approach for GBM treatment.
View Article and Find Full Text PDF

Self-assembled lipid nanoparticles (LNPs) are essential nanocarriers for drug delivery. Functionalization of LNPs with ionizable lipids creates pH-responsive nanoparticles that change structures under varying pH conditions, enabling pH-triggered drug release. Typically, bicontinuous cubic phase nanoparticles (Cubosomes) and lamellar structured vesicles (Liposomes) differ in lipid packing statuses, affecting drug release and cellular uptake.

View Article and Find Full Text PDF

2-Hydroxyoleic acid (2-OHOA) has gained attention as a membrane lipid therapy (MLT) anti-cancer drug. However, in the viewpoint of anti-cancer drug, 2-OHOA shows poor water solubility and its effectiveness still has space for improvement. Thus, this study aimed to overcome the problems by formulating 2-OHOA into liposome dosage form.

View Article and Find Full Text PDF

A potent nontoxic antitumor drug, 2-hydroxyoleic acid (, 2OHOA) used for membrane lipid therapy, was selected as a self-assembly inducer due to its ability to form nanoparticles (NPs) in water. For this purpose, it was conjugated with a series of anticancer drugs through a disulfide-containing linker to enhance cell penetration and to secure drug release inside the cell. The antiproliferative evaluation of the synthesized NP formulations against three human tumor cell lines (biphasic mesothelioma MSTO-211H, colorectal adenocarcinoma HT-29, and glioblastoma LN-229) showed that nanoassemblies - exhibit antiproliferative activity at micromolar and submicromolar concentrations.

View Article and Find Full Text PDF

Modulation of the endogenous cannabinoid system has been suggested as a potential anticancer strategy. In the search for novel and less toxic therapeutic options, structural modifications of the endocannabinoid anandamide and the synthetic derivative of oleic acid, Minerval (HU-600), were done to obtain 2-hydroxy oleic acid ethanolamide (HU-585), which is an HU-600 derivative with the anandamide side chain. We showed that treatment of SK-N-SH neuroblastoma cells with HU-585 induced a better anti-tumorigenic effect in comparison to HU-600 as evidenced by 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide assay, colony-forming assay, and migration assay.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!